Epizyme to Participate in Three Upcoming Conferences

Cambridge, MA, August 31, 2011 – Epizyme, Inc., a company leading the discovery and development of targeted therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held the first week of September in Boston.

• Mr. Jason Rhodes, Executive Vice President and CBO, will participate on a panel titled, “Bridging the Gap Between the Sell- and Buy-sides: Current Approaches Versus Best Practice,” at the MassBIO Business Development committee meeting on Tuesday, September 6^th at 3:00PM
• Mr. Rhodes will also present at the Stifel Nicolaus Healthcare Conference on Friday, September 9^th at 9:10AM in the Leverett Room of the Four Seasons Hotel
• Dr. Robert Gould, President and CEO, will present at the BioPharm America/MassBIO Investor Forum on Friday, September 9^th at 10:00AM in the Otis Room of the Westin Waterfront Hotel

About Epizyme

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-­defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-­driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. www.epizyme.com

Media Contacts

Jennifer Conrad or Chris Erdman

MacDougall Biomedical Communications

781.235.3060